2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-6) by The Life Science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the U.S. and Canada
Manufacturer The Life Science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the U.S. and Canada | Model: AGX806 | Available Worldwide
2019-nCoV Nucleocapsid Recombinant Antigen,full length (Ag-6)
2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-6)
Request Pricing
The Life Science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the U.S. and Canada
Receive your quote directly from the manufacturer.
Quick Links
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the virus strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus closely related to the SARS virus. A SARS-CoV-2 nucleocapsid antigen can be used to support the detection of SARS-CoV-2 (COVID-19, 2019-nCoV).
Product Overview
2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-6)
Manufacturer The Life Science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the U.S. and Canada | Available Worldwide
Be the first to review this product
